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Abstract
Background: “High risk” Human Papillomavirus strains are the causative agents of the vast majority of carcinomas
of the uterine cervix. In these tumors, the physical integration of the HPV genome is a frequent, though not
invariable occurrence, but the constitutive expression of the E6 and E7 viral genes is always observed, suggesting
key roles for the E6 and E7 oncoproteins in the process of malignant transformation. The “intracellular antibody”
technology using recombinant antibodies in single-chain format offers the possibility of targeting a protein in its
intracellular environment even at the level of definite domains thus representing a valuable strategy to “knock out”
the function of specific proteins.
Methods: In this study, we investigate the in vitro activity of two single-chain antibody fragments directed against
the “high-risk” HPV 16 E7 oncoprotein, scFv 43M2 and scFv 51. These scFvs were expressed by retroviral system in
different cell compartments of the HPV16-positive SiHa cells, and cell proliferation was analyzed by Colony
Formation Assay and EZ4U assay. The binding of these scFvs to E7, and their possible interference with the
interaction between E7 and its main target, the tumor suppressor pRb protein, were then investigated by
immunoassays, PepSet™technology and Surface Plasmon Resonance.
Results: The expression of the two scFvs in the nucleus and the endoplasmic reticulum of SiHa cells resulted in
the selective growth inhibition of these cells. Analysis of binding showed that both scFvs bind E7 via distinct but
overlapping epitopes not corresponding to the pRb binding site. Nevertheless, the binding of scFv 43M2 to E7 was
inhibited by pRb in a non-competitive manner.
Conclusions: Based on the overall results, the observed inhibition of HPV-positive SiHa cells proliferation could be
ascribed to an interaction between scFv and E7, involving non-pRb targets. The study paves the way for the
employment of specific scFvs in immunotherapeutic approaches against the HPV-associated lesions.
Background
In recent years, recombinant antibodies have emerged as
powerful tools among several different strategies for pro-
tein “knock out” [1]. Antibodies in single-chain format or
single-chain variable fragments (scFvs) are extremely ver-
satile since they can be easily delivered and opportunely
manipulated. ScFvs can be either conjugated to different
kinds of molecules, such as radioisotopes and toxins, or
expressed as intracellular antibodies (intrabodies) in a
specific intracellular compartment, where they can inter-
fere with the function of the targeted antigen even at the
level of specific domains [2].
The “intrabody” technology offers significant advan-
tages over alternative gene therapy methods given that
HPV oncogenic capacity is largely due to the interaction
of viral proteins with cellular targets [3,4].
The E7 oncoprotein of the “high risk” human papillo-
maviruses (HPVs) is a tumor-specific antigen that plays
* Correspondence: luisa.accardi@iss.it
1Department of Infectious, Parasitic and Immunomediated Diseases, Istituto
Superiore di Sanità, Rome, Italy
Full list of author information is available at the end of the article
Accardi et al. BMC Cancer 2011, 11:17
http://www.biomedcentral.com/1471-2407/11/17
© 2011 Accardi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.a crucial role in virus-associated tumorigenesis, mainly
by promoting cellular proliferation [5,6]. Development
of therapies effective selectively at the tumor site, thus
avoiding significant adverse effects on non-cancerous
cells, is the main challenge in the search for new cancer
treatments. Because E7 expression is restricted to the
infected or transformed cells, therapeutic approaches
targeting this protein offer great advantages in terms of
specificity. E7 has both nuclear and cytoplasmic localiza-
tion, and a pleiotropic action: it influences transcrip-
tional and non transcriptional cell-cycle control
checkpoints, subverts the expression of genes not
involved in cell cycle control, and deregulates cellular
energy metabolism and apoptosis [7]. More than twenty
E7-binding cellular proteins have been identified so far,
including transcription factors such as the members of
the E2F family, but the main E7 targets are the members
of the retinoblastoma family of “pocket proteins”,p R b ,
p107 and p130. E7 binds to these proteins mostly
through the strictly conserved LXCXE motif (aa LYCYE
at position 22-26 in HPV16 E7) but also through the
CR3 region present at its COOH-terminus [8-10]. Bind-
ing of E7 to pRb causes the release of the E2Fs and the
consequent activation of genes that encode proteins pro-
moting cell cycle progression to S phase: this association
is considered the main, but not unique, cause of E7
oncogenic activity [11,12]. In fact E7 proteins from non-
oncogenic genotypes, which bind to the pocket proteins
with a lower affinity, are still able to deregulate cell
cycle, and some E7 activities are detectable in vivo in
pRb-null tissues [13]; furthermore, E7 promotes cell
transformation by inducing an increase in protein kinase
B phosphorylation [14,15]. Several oncogenic mechan-
isms not involving E7-pRb binding have been also
reported for some HPV types [16-18].
We have previously reported the selection by “Phage
Display” of three scFvs (scFv 32, 43, 51) against recom-
binant HPV16 E7 (16E7). One of these, scFv 43, charac-
terized for its biological activity, showed a specific
antiproliferative activity on HPV16-positive SiHa cells.
This scFv was then modified by site-directed mutagen-
esis to generate scFv 43M2, which displayed comparable
binding characteristics but improved stability [19,20].
Here we investigate the effect of scFv 43M2 and scFv
51, the most stable scFv fragments that we have gener-
ated, on cell proliferation. A significant antiproliferative
effect was specifically observed in HPV16-positive SiHa
cells, particularly when the scFvs were targeted to the
endoplasmic reticulum, thus confirming the results
obtained previously [19]. To explore the mechanisms of
action underlying this activity, we looked at the binding
of the two scFvs to E7, particularly in relation to the pRb
binding site. Using two different deletion mutants, it
was established that both scFvs bind to the N-terminal
E7 sequence. The epitope mapping of the two scFvs was
investigated by PepSet™assay. The possible scFvs reci-
procal interference and the scFv 43M2 interference with
pRb in the competitive binding to E7 were analyzed by
Surface Plasmon Resonance (SPR). The results, as a
whole, suggest that the epitopes recognized by the two
scFvs on E7 are distinct but overlapping, and that the
mechanism underlying the observed inhibition of prolif-
eration is probably pRb-independent.
Methods
Plasmids, scFv fragments and cloning
The scFvs 43M2 and 51 were previously obtained by
selection from the ETH-2 library of human recombinant
antibodies [21]. In this library, the scFvs coding
sequences are cloned in the pDN332 phagemid vector
under lacZ-promoter control, in fusion with a FLAG-tag
and a His-tag at their COOH-terminus. The scFv 43M2
and 51 sequences were subcloned into the Nuclear (N)
and Sekdel (SD) scFvEx vectors [19], obtaining scFv
43M2N, scFv 43M2SD, scFv 51N and scFv 51SD.
Briefly, the coding sequences were PCR-amplified (95°C
for 1 min, 50°C for 1 min, 74°C for 1 min, 35 cycles)
using the SalsekD-NotsekR2 pair of primers (restriction
sites are underlined): SalsekD, 5’CGGCGTCGACCC-
GAGGTGCAGCTGGTGG 3’; NotsekR2, 5’CGGC-
GCGGCCGCTTTGATTTCCACCTTGGTCCC 3’.T h e
PCR products were double-digested with SalI/NotI, gel-
purified and ligated into scFvExpress vectors with sig-
nals for localization in the nucleus (scFvEx-N) and
endoplasmic reticulum (scFvEx-SD), digested with the
same enzymes. The scFvs expressed from the recombi-
nant plasmids do not retain the original FLAG-tag and
the His-tag sequences, but have acquired at their
COOH-terminus a c-myc-tag, useful for detection in
immunoassays.
The scFv 43M2 and 51 coding sequences, provided
with specific signals for intracellular localization, were
cloned into the pLNCX retroviral vector. Two con-
structs for each scFv, respectively targeting the nucleus
(M2N, 51N) and the endoplasmic reticulum (M2SD,
51SD) were obtained.
The scFv coding sequences were PCR-amplified (95°C
for 1 min, 55°C for 1 min, 74°C for 1 min, 35 cycles) using
the Hind-NucDir and the Cla-NucRev pair of primers on
the linearized scFvEx-N templates, and the Hind-Sekdel-
Dir and Cla-SekdelRev pair of primers on the linearized
scFvEx-SD templates. The sequences of the primers used
are the following (restriction sites are underlined): Hind-
NucDir, 5’CCGGAAGCTTCCATGGCCGAGGTGCA-
GCTG 3’; Cla-NucRev, 5’ CCGGATCGATCTATGCGG-
CCCCATTCAGATCC 3’;H i n d - S e k d e l D i r ,5 ’ CCGG-
AAGCTTCCATGGGATGGAGCTGTATCATCC 3’;C l a -
SekdelRev, 5’ CCGGATCGATCTAGACTACAGCT
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digested with HindIII/ClaI and ligated into the pLNCX
vector digested with the same enzymes. The ligation pro-
ducts were used to transform E. coli XL1-blue cells.
The recombinant pGEX-2T vector expressing the full-
length 16 E7 was kindly provided by Dr A. Venuti [22]
and those expressing the 16E7 N-term, 16E7C-term and
pRb as GST-fused proteins were previously described
[23,24].
Cell lines, transfection, transduction and analysis of the
scFvs expression by WB and immunofluorescence
staining
Two cervical epithelial tumor cell lines, the HPV16-
positive SiHa (ATCC HTB 35), and the HPV-negative
C33A (ATCC HTB 31) cells and the 293-derived Phoe-
nix packaging cells (ATCC 3444) were used in this
study. Phoenix cells contain the stably integrated gag,
pol and env genes of the Moloney leukaemia virus,
necessary for retrovirus assembly and replication. SiHa,
C33A and Phoenix cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% heat-
inactivated fetal calf serum (FCS), 100 units/ml penicil-
lin, 100 μg/ml streptomycin and 2 mM glutamine. The
scFv-expressing recombinant constructs (M2N, 51N,
M2SD, 51SD) and the empty pLNCX vector as a con-
trol, were used to transiently transfect the Phoenix
packaging cells at 60% confluence using the JetPEI
transfection reagent (Polyplus transfection) according to
the manufacturer’s recommendations. At 48 h post-
transfection, scFv expression was monitored by WB ana-
lysis. Cell lysates in 2× SDS loading buffer were sepa-
rated in 12% SDS-PAGE, blotted onto PVDF membrane
and incubated with rabbit anti-c-myc mAb (clone 9E10,
Sigma) followed by GAR-HRP IgG (Calbiochem, Cam-
bridge, UK) incubation. The immunocomplexes were
revealed by chemiluminescence detection. At 48 h post-
transfection, the virus-containing cell culture medium
from transfected cells was filtered with 0.45 μmf i l t e r s
and used to transduce the SiHa cells or the control
C33A cells at 60% confluence. At 24 h post-transduc-
tion, cells were subcultured and plated under neomycin-
selection (0.8 mg/ml). ScFv expression in transduced
SiHa cells was analysed by immunofluorescence and
WB. For immunofluorescence staining, performed
before cell confluence, cells were fixed with 3.7% paraf-
ormaldeyde for 20 min at room temperature followed
by permeabilization with 0.1% Triton X-100 in PBS for
5 min. Cells were washed with PBS and incubated for
1 h with rabbit anti-c-myc mAb, which recognizes the
c-myc-tag at the scFvs COOH-terminus, followed by
incubation with GAR-FITC (Cappel), both diluted 1: 50.
Samples were examined using a Leitz fluorescence
microscope (Germany). Cell nuclei were stained with
DAPI (Invitrogen). WB was performed on SiHa cell
lysates with the same procedures utilized for Phoenix
cells.
Cell proliferation and viability assays
To test cell proliferation, a colony formation assay
(CFA) was performed 24 post-transduction. Cells were
trypsinized, diluted 10, 100o r1 0 0 0t i m e s ,a n dg r o w n
for 8-15 days under G418 selection. To visualize the
colonies, cells were washed in PBS, fixed and stained on
the plates with crystal violet in 20% methanol.
Cell viability was tested by the EZ4U method (Biome-
dica Gruppe, Austria), which is based on the ability of
living cells to reduce uncoloured tetrazolium salts to
colored formazan derivatives. The assay was performed
according to the manufacturer’s instructions. Briefly, the
cells were plated at decreasing dilutions on a 96-well
plate and cultivated for 1-2 weeks under G418 selection.
After addiction of substrate and activator the cells were
incubated at 37°C for 3 h. The OD was measured at 450
and 620 nm as a reference, to correct the values for
nonspecific background.
Protein expression and purification
Full-length 16E7, two 16E7 deletion mutants, one repre-
senting the NH2-terminal half (16E7 N-term, aa 1-52)
and the other representing the COOH-terminal half
(16E7 C-term, aa 44-98) of the 16E7 protein, and the pRb
protein, were expressed in E. coli as GST-fusion proteins.
DH5a cells were transformed by the recombinant pGEX-
2T vectors and purified using GST-Sepharose (Invitro-
gen) according to the manufacturer’s instructions. The
scFv expression was induced using 2 mM IPTG for 4 h at
room temperature (RT) in HB2151 E. coli cells trans-
formed by the recombinant pDN332 phagemid vectors.
ScFv51 was extracted from the bacterial periplasm, where
it is secreted by virtue of the pelB peptide leader present
upstream the antibody sequence [21]. ScFv43M2 was
extracted from the total bacterial lysate. Briefly, bacteria
recovered from a 1-liter culture were re-suspended in 50
ml of lysis buffer (50 mM Tris-HCl, pH 7.0, 1% Triton X-
100, 1 mM EDTA, 1 mM EGTA, 0.5 M NaCl) containing
complete EDTA-free protease inhibitors (Roche), soni-
cated and incubated for 20 min on ice. The lysate was
centrifuged at 12,000g for 10 min at 4°C and the superna-
tant processed to purify the antibody fragments. In all
cases, purification was carried out by affinity chromato-
graphy on protein A-Sepharose CL-4B (Amersham
Bioscience) according to the manufacturer’si n s t r u c t i o n s .
Purity of the proteins was evaluated by Coomassie blue
staining after SDS-PAGE, and protein concentration
determined by Bradford assay. The identity of the puri-
fied antibody fragments was confirmed by immunoassays
using the mouse M2 mAb (2 μg/ml, Sigma, St. Louis,
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COOH-terminus, followed by incubation with GAM-
HRP diluted 1: 10000 (Amresco, Solon, OH). Chemilumi-
nescence was carried out using the Super Signal West
Pico Chemiluminescent Substrate (Pierce, Rockford, IL).
Immunoassays for the determination of scFv specificity
and reactivity
The full-length and deleted GST-E7 fusion proteins were
immobilized on a 96-well plate (300ng/well) to perform
ELISA, or separated by SDS-PAGE and transferred onto
PVDF membrane (Millipore, Bedford, MA) to perform
WB. For ELISA, the purified scFvs (3 μg/ml) followed by
mouse M2 mAb (2 μg/ml) (Sigma, St. Louis, MO) or anti-
GST mAb at 1: 1000 dilution (Santa Cruz, CA) as primary
antibodies (or no antibody as a control), and GAM-HRP
diluted 1: 10000 (Amresco,S o l o n ,O H )a sas e c o n d a r y
antibody. The immunocomplexes were revealed by Che-
miluminescence as indicated above. For WB, the mem-
brane was cut into strips (1 μg of each protein/strip) that
were incubated with the same primary and secondary anti-
bodies used in the ELISA. For the colorimetric reaction, a
TMB substrate kit for peroxidase (Vector Laboratories,
Inc.; Burlingame, CA) was used as a substrate.
PepSets™ technology
PepSets™ technology (Mimotopes Pty Ltd, Clayton, Vic-
toria, Australia) was employed for identification of the
amino acids involved in the binding of E7 to the scFv
43M2 and 51 according to the method previously
described [25,26]. The rod-bound peptides were assayed
for their ability to physically interact with the purified
scFvs. The amount of protein captured by each rod was
detected via a modified immunoenzyme assay using
mouse M2 mAb (1 μg/ml) and GAM-HRP at a 1: 1000
dilution. At the end of the procedure, plates were ana-
lyzed in a microtiter reader at a wavelength of 492 nm.
Surface Plasmon Resonance by BIAcore
Surface plasmon resonance measurements were carried
out using a BIAcoreX instrument (GE Healthcare)
equipped with two flow-cell sensor chips. The E7
recombinant protein was immobilized to the Biacore
CM5 sensor chip using conventional amine coupling:
activation of the carboxymethylated dextran surface by a
mixture of 0.05 M N-hydroxysuccinimide and 0.2 M
N-ethyl-N0-3-(dimethylaminopropyl) carbodiimide hydro-
chloride. The reaction was performed by injecting E7 at a
flow rate of 5 μl/min at 25°C for 7 min. Residual activated
groups were blocked with 1 M ethanolamine-HCl (pH
8.5). The experiments were performed in HBS-P (10 mM
Hepes pH 7.4, 0.15 M NaCl, 0.005% (v/v) surfactant P20)
at 25°C. For the epitope mapping experiment the E7 sur-
face was saturated by injection of the first scFv at a flow
rate of 10 μl/min. Then, 40 μl of the second scFv were
injected at 500 nM; both the scFv combinations were
assayed. The response of the biomolecular interaction,
expressed in arbitrary units (Response Units, RU), was
monitored as a function of time (sensorgram). No nonspe-
cific binding was revealed by the reference flow-cell. The
interaction of scFv 43M2 with E7 in the presence of GST-
pRb was investigated by injecting scFv 43M2 (200 nM)
over E7 surface at a flow rate of 20 μl/min, in the absence
and in the presence of increasing concentrations of GST-
pRb (0-400 nM). The RU values of scFv 43M2 sensor-
grams were measured 20 s after the injection and their
variation in relation to the GST-pRB concentration was
analysed with KaleidaGraph Version 4.0.
Results
Antiproliferative effect of the anti-E7 scFvs
We investigated whether the anti 16E7 scFv 43M2 and
scFv 51, previously selected for their recognized high
stability [20 and unpublished results], could specifically
affect HPV16-positive SiHa cells proliferation upon
intracellular expression.
HPV16-positive SiHa and HPV16-negative C33A cells
were transduced with recombinant retroviruses expres-
sing the scFvs in the nucleus and the endoplasmic reticu-
lum. The localization of the expressed scFvs in cell
nucleus and endoplasmic reticulum was chosen on the
basis of the results obtained previously [19]. The retro-
viral system was utilized in order to obtain scFv expres-
sion in a higher number of cells, as compared to that
observed after plasmid transfection, which was the
method utilized previously. Indeed, the use of retroviral
system allowed us to obtain a considerably higher per-
centage of scFv-expressing cells, as assessed by counting
immunofluorescent scFv-positive cells. Twenty-four
hours post-transduction, scFv-expressing cells were more
than 30%, in comparison to 5-10% of previous experi-
ments using transfection [19], reaching a value of 70%
after a few passages under G418 selection (Figure 1).
Cell proliferation was analyzed by colony forming
assay (CFA), performed after a 14-day G418 selection
(Figure 2A). The histogram in Figure 2B shows the
mean values of three independent experiments. The
colonies obtained from cells transduced with the M2N
and M2SD retroviruses were 57% ± 3.1 and 38% ± 1.8
of those obtained from the pLNCX retrovirus-trans-
duced cells, respectively; the colonies from the 51N- and
51SD-transduced cells were 62% ± 6.7 and 9% ± 3.8
respectively of the control cells transduced. Statistical
significance of the data, with a p value <0.01, was
assessed using the c
2 test. Of note, in this assay the per-
centage of proliferating cells was calculated by consider-
ing the proliferation of both SiHa and C33A cells
transduced with the empty retroviral vector as the
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cerning proliferating C33A cells transduced with the
recombinant retroviral vectors often exceed 100%.
Cell viability of the scFv 43M2-transduced cells was
investigated by the EZ4U assay, based on the capability
of living cells to reduce uncolored tetrazolium salts into
intensely colored formazan derivatives, assessable by an
OD450 absorption reading. The OD450 values obtained
for SiHa cells expressing M2N and M2SD were respec-
tively 58% and 33% of control (Figure 2C), whereas no
appreciable decrease of the OD450 values was observed
in C33A cells, confirming the specificity of the results.
These findings are in agreement with the cell prolifera-
tion values obtained by CFA. Notably, in both assays,
the highest level of inhibition in cell proliferation and
viability was obtained by the scFvs expressed in the
endoplasmic reticulum, in agreement with the results
obtained previously with a different scFv [19].
ScFv binding to 16E7
The E7 ability to sustain proliferation is largely based on
its interaction with several cellular targets the most
important of which is pRb [7-18,27-29]. To possibly elu-
cidate whether the mechanism underlying the anti-E7
scFvs antiproliferative activity was due to a competition
with pRb for binding to the oncoprotein, we investigated
the scFvs-binding epitopes of E7.
Binding of scFv 43M2 and scFv 51 to 16E7 was ana-
lyzed by Western blotting and ELISA, using two deletion
mutants representing the NH2-terminal half (16E7 N-
term, aa 1-52) or the COOH-terminal half (16E7 C-term,
aa 44-98) of 16E7 (Figure 3A). WB results (Figure 3B)
showed that both scFvs were able to bind to the 16E7
NH2-terminal half, but not to the COOH-terminal half.
These results were confirmed by ELISA (Figure 3C).
Figure 1 ScFvs expression in SiHa cells by retroviral system.
SiHa cells transduced with the scFv51-expressing retroviruses
carrying nuclear localization signal (51N, top panel, right) or
endoplasmic reticulum localization signal (51SD, bottom panel,
right) were analyzed by immunofluorescence. The transduced cells
were fixed 24 h post-transduction with 4% paraformaldehyde and
the scFv localization was detected by a mouse anti-myc mAb
followed by an anti-mouse FITC-conjugated mAb, as a secondary
antibody. The nuclei of transduced cells, shown on the left in top
and bottom panels, were stained with PI.
Figure 2 Antiproliferative effect of the anti-E7 scFvs. Proliferation
of SiHa cells transduced with the 43M2N, 43M2SD, 51N, 51SD
retroviruses and the pLNCX-retrovirus as a control was analyzed by
CFA. Twenty-four hours post-transduction, the cells were G418-
selected. After 2 weeks the cells were fixed with 20% methanol and
stained with crystal violet and the colonies counted for each plate. The
number of colonies was determined also for the C33A control cells
transduced with the same retroviruses used in SiHa cells. Panel A:
colonies obtained in a representative experiment are shown. The
number of colonies in each plate was determined and expressed as a
percentage of the number of cells transduced with the empty virus.
Panel B: the histogram shows the mean percentage of colonies
obtained from the recombinant retroviruses, ± standard deviation (SD)
with respect to the control. The mean values ± SD were calculated
from the results of three independent experiments performed using
the HPV16-positive SiHa (in grey) or the HPV-negative C33A cells.
Panel C: Analysis of cell viability by EZ4U assay. The assay is based on
tetrazolium salts as indicators of cell viability. The reduction of the
OD450 value, corrected by subtracting the OD620 value, is an indicator
of cell death. SiHa cells transduced with 43M2N, 43M2SD and pLNCX
retroviruses were grown in the wells of a 96-wells plate and the OD
values were measured after 3 hours of incubation with the substrate.
The percentage of the OD450 values of the scFv-expressing cells,
corrected for the background, is reported in the figure with respect to
the control cells (pLNCX). *Statistically significant data.
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The linear amino acid domains of 16E7 involved in the
binding to scFv 43M2 and 51 were analyzed by the
PepSets™ technique. In view of the above results, oligo-
peptides covering the region 1-54 of the 16E7 amino
acids were used. Oligopeptides were synthesized from
COOH- to NH2-terminus on polypropylene rods as 12-
mers, with a 9 amino acid-overlap. Rod-bound peptides
(PEP) were then assayed by ELISA for their ability to
bind to the purified scFv 43M2 and scFv 51. The aver-
age OD492 values of two highly reproducible experi-
ments, are shown in Figure 4. The binding pattern of
Figure 3 Mapping of the scFv 43M2 and 51 epitopes on E7 protein by immunoassays. Western Blotting and ELISA were performed using
as antigens two 16E7 deletion mutants respectively representing NH2-term and COOH-term of the 16E7 protein. Panel A: schematic
representation, with functional domains, of full-length 16E7 and 16E7 deletion mutants produced as GST-fusion proteins and used for the
mapping of the scFvs. Panel B: Western blotting. Each antigen-containing strip was incubated with the purified scFvs 43M2 (M2), 51 and a
mouse anti-Flag mAb. The control stripes were incubated with commercial anti-16E7 (M) and anti-GST monoclonal antibodies (mAb) in mouse,
an in-house anti-16E7 polyclonal antibody (P) or no antibody (CTR). An anti-mouse peroxidase-conjugated mAb was used as a secondary
antibody in all cases. The immunocomplexes were visualised by chemioluminescence. Panel C: ELISA. The coating was performed with the same
proteins utilised for WB, and the incubation performed with the same primary and secondary antibodies, as indicated. The immune-complexes
were revealed following incubation with the peroxidase substrate by reading the OD at 450 nm (OD450). The dashed lines represent the cut-off
values for each experiment, corresponding to the OD450 values obtained using the anti-GST mAb.
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ven peptides utilized, covering aa 1-42 of the E7 mole-
cule, with a binding activity which increased from the
first to the fourth peptide, reaching the maximum with
PEP 10-21. Limited or null binding activity relative to
PEP 16-27, 19-30 and 22-33 was observable for both
scFvs. Interestingly, these are the only peptides contain-
ing the entire LYCYE pRb binding site; this result sug-
gests it is unlikely that the two scFvs could compete
with pRb for binding to E7. Furthermore, in the 34-54
aa region the two scFvs showed a different binding pat-
tern, as scFv 43M2 but not scFv 51 bound to PEP 34-45.
The EYM (aa 10-12) and GQA (aa 43-45) sequences
(both shown in bold in Figure 4), appear to play a role
in the binding and could therefore represent part of the
scFv binding site on E7. Nevertheless, scFv 51 scarcely
bound to PEP 34-45, in which GQA is located at the
COOH terminus. Furthermore, both the scFvs bound
weakly to PEP 1-12, in which EYM is located at the
COOH-terminus, but the scFvs binding activity towards
the peptides increased with the shift of the position of
the presumed epitopes towards the NH2-terminus. This
different binding activity could be ascribed to the oligo-
peptide growth proceeding from COOH- to NH2-termi-
nus, with the COOH- terminus bound to the rod
possibly resulting in less accessibility for the physical
interaction with the scFvs.
In previous experiments, we observed that scFv 43M2
was able to bind to recombinant E7 proteins of different
HPV genotypes, even if with different specificities. This
scFv showed a strong reactivity against the 16E7, lower
reactivity against the E7 of HPV33 (33E7) and no reactivity
Figure 4 Mapping of the scFv 43M2 and 51 epitopes on E7 protein by Pep-set™.T h eH P V 1 6E 7a m i n oa c i ds e q u e n c ef r o m1t o5 4 ,
reproduced as 12-mers with a 9 amino acid overlap, was synthesized on 15 different polypropylene rods. The histogram represents the ability of
each 12-mer oligopeptide to bind the purified scFvs as indicated in the figure. Values shown are the averages of those obtained in two different
experiments with similar results. The amino acid sequences identified as probable binding epitopes are in bold. The corresponding amino acid
sequences for HPV16, HPV18 and HPV33 E7 are aligned in the bottom part of the figure. The conserved residues of HPV18 and 33 in comparison
with HPV16 E7 are in bold.
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Comparison of the amino acids of 33E7 and 18E7 corre-
sponding to positions 10-12 and 43-45 of 16E7, is shown
in Figure 4 (bottom section). A high similarity between
16E7 and 33E7, with only one difference at position 12 (V
instead of M) and a complete divergence between 16E7
and 18E7, with only one residue (Q) conserved at position
44, are observable. These findings support the hypothesis
that these residues could play a role in the specific scFv
43M2 binding to 16E7.
Surface Plasmon Resonance analysis of the scFv binding
to E7
The scFv 43M2 and scFv 51 epitope specificity patterns
of binding to E7 were elucidated by Surface Plasmon
Resonance (SPR) using a BiacoreX-instrument. First we
analyzed the binding capacity of each purified scFv to
the E7 protein covalently coupled to a CM5 sensor chip.
Then, to determine whether the scFvs epitopes were
overlapping, each scFv was run as an analyte over the
immobilized E7 after the binding of the other one. As
an example, Figure 5A shows that scFv 43M2 injected at
500 nM was still able to bind to the E7 sensor chip
saturated with scFv 51, suggesting the binding epitopes
o ft h et w os c F v st ob ed i s t i n c t .T h es a m er e s u l tw a s
obtained when the injections of the two scFvs were per-
formed in the reverse order (not shown). Nevertheless,
the RU value that expresses the binding of the second
scFv injected was reduced when compared to that
obtained when performing the injections in the reverse
order (data not shown). This probably indicates an
interference between the two scFvs due to their overlap-
ping binding sites.
By SPR we further investigated the possibility of an
overlap between the scFv 43M2 and the pRb epitopes,
that could influence if not impede pRb binding to E7.
Purified pRb at increasing concentrations in the 0-400
nM range was run over the E7 sensor chip followed by
the injection of scFv 43M2 (200 nM) (Figure 5B). Inter-
estingly, a non competitive inhibition was observed; in
fact, with increasing bound pRb, the scFv 43M2 binding
to the immobilized E7 was progressively inhibited. This
binding pattern can be better appreciated in the ela-
boration with Kaleidograph shown in Figure 5C. Unfor-
tunately, it was not possible to employ the GST-pRb
fusion protein at the saturating concentration because
pRB dissociation was hampered at concentrations
higher than that used, causing chip damage.
Discussion
Many studies have shown that the transforming activity of
the “high risk” HPV E6 and E7 proteins resides in the
capacity to bind to and inactivate cellular targets, including
but not limited to the p53 and pRb oncosuppressor
proteins, which are respectively better known targets. Inhi-
bition of E6 and/or E7 function has been shown to inhibit
the growth of HPV-positive cervical cancer cells in a num-
ber of experimental systems [30-33]. Therefore, the search
for suitable inhibitors of these oncoproteins is of great
relevance in terms of cancer therapy.
We have previously demonstrated the inhibition of
HPV16-positive SiHa cell proliferation by an anti-16E7
scFv [19]. In this study we present the anti-proliferative
activity of two other anti-16E7 scFvs. We found that the
two scFvs negatively affect cell proliferation when
expressed in nucleus and ER of SiHa cells, and have no
effect in the HPV-negative C33A cells, showing the spe-
cificity of their activity.
The most efficient inhibition of cell proliferation was
obtained when the scFvs were expressed in the endoplas-
mic reticulum; this is probably ascribable to the high stabi-
lity of antibody fragments when they are retained in this
compartment, and it has already been discussed elsewhere
[19]. E7, previously regarded as primarily a nuclear pro-
tein, has been found both inside and outside the cell
nucleus, and recent findings support its functional rele-
vance in non-nuclear compartments. The presence of E7
in the ER and in the cytoplasm has been suggested and
demonstrated, as well as the E7 interaction with a number
of cytoplasmic proteins [33-35]. As an example, specific
association of the 16E7 with g-tubulin has been shown
and suggested to contribute to E7-induced centrosome
overduplication, which is considered one of the mechan-
isms underlying the E7 ability to deregulate cell prolifera-
tion [27]. Therefore, even though the mechanisms
underlying the anti-E7 scFvs antiproliferative effect are not
yet fully understood, it is very likely that these molecules
exert their activity by functioning outside the nucleus.
We then addressed the molecular mechanisms under-
lying the scFvs anti-proliferative activity by analyzing the
scFvs-binding epitopes of E7. Since the relationship
between the E7 activity and its interaction with pRb is
well established, we focused on the possible interaction
of the scFvs with the pRb binding site. In this regard,
we wondered whether the observed inhibition of cell
proliferation by the scFvs could be due to competition
with pRb for binding to E7. By immunoassays we
showed the epitopes of both the scFvs to map to the E7
NH2-terminal half (aa 1-52). Analysis by PepSet™tech-
nology and SPR permitted us to investigate different
aspects of the scFv binding. These different methodolo-
gies allowed us to analyze the binding to linear epitopes
(PepSet™), as well as the binding between two mole-
cules in their steric configuration (SPR).
By PepSet™analysis, it was shown that both the scFvs
bound predominantly to PEP 10-21 and with low or
null efficiency to the peptides containing the main pRb
binding site. Two sequences each consisting of three
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Page 8 of 12Figure 5 Mapping of the scFv 43M2 and 51 epitopes on E7 protein by Surface Plasmon Resonance. Panel A: the sensorgram shows the
relative binding of the two scFvs to the recombinant 16E7 immobilized on the sensor chip. The scFv 51 at saturating concentration was
injected followed by scFv43M2. The curves show that scFv 43M2 and 51 have distinct epitope binding sites on E7. Panel B, top: the scFv 43M2
binding curves in the sensorgram were obtained by injecting scFv43M2 at a constant concentration (200 nM) following the binding of GST-pRb
injected over the E7 sensor chip at different concentrations in the 0-400 nM range. Panel B, bottom: the Response Unit (RU) values for scFv
43M2 (dashed line) as a function of GST-pRb concentrations were measured 20 s after the end of each injection. The results were elaborated
with KaleidaGraph Version 4.0.
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E7-binding epitopes of both the scFvs. Interestingly,
when observing the binding activity in relation to the
position of such epitopes in the respective oligopeptides,
localization at the COOH-terminus appeared to nega-
tively influence the binding. Therefore, the position of a
specific domain in a given context seems to be a key
aspect of the binding even when considering a linear
arrangement. However, some differences between the
two scFvs in terms of E7 binding were highlighted by
this analysis, supporting the argument that the epitopes
of the two scFvs are at least partially distinct.
The difference between the epitopes of scFv 43M2 and
scFv 51 on E7 binding was confirmed by SPR. In this
experiment we observed that each scFv could bind to
the E7 immobilized on the chip even when the other
scFv was still bound. Furthermore, we observed a non-
competitive inhibition by pRB, of the binding between
scFv 43M2 and E7, where increasing concentrations of
p R bw e r ea b l et op r o p o r t i o n a l l yr e d u c et h eb i n d i n go f
43M2 to the E7 immobilized on the chip. This finding
is only apparently in contrast with the PepSet™results
suggesting that the LYCYE motif (pRb binding site) is
not directly involved in the scFv binding. In fact, the
adjacent amino acids outside the LYCYE pocket could
contribute to the binding when E7 is partially folded in
its three-dimensional structure (see SPR analysis). How-
ever, we cannot completely exclude the possibility that
the inhibition of scFv 43M2 binding by pRb is simply
due to steric hindrance of the recombinant GSTpRb
molecule, which is larger than the scFv molecule
(130 kDa versus 27 kDa). This potential drawback can-
not be circumvented in this experimental model.
Of note, in pRb-null Saos-2 cells transfected with the
scFv 43M2- and pRb-expressing plasmids, we did not
o b s e r v ear e s c u eo fp R bl e v e lw h e ne x p r e s s i n gs c F v
43M2 in the ER (data not shown), supporting the
hypothesis that the proliferation inhibition by scFv
43M2 is not pRb-dependent.
Our results on the analysis of scFvs binding to E7 sup-
port the possibility that interaction with regions other
than the E7 LYCYE motif underlies the scFvs activity.
We cannot exclude the possibility that interaction with
other cellular components could be involved in this
inhibition. Indeed, pRb tumor suppressor and the other
pocket proteins are expressed in different relative
amounts according to the differentiation state of the tis-
sue [8,9]. It has also been observed that the E7 NH2-
terminal region upstream of the LXCXE pocket, is
involved in the degradation of the pRb family of pro-
teins, even though it is not involved in their binding to
E7 [36]. A number of studies have described non-pRb
E7 targets which are important in cervical dysplasia or
invasive cancer etiology [13-18,27] as well as models by
which E7 destabilizes pRb indirectly through other cellu-
lar components [28,29].
Furthermore, the E7 NH2-terminus has been recently
described as an intrinsically disordered or “natively
unfolded” domain, able to adopt different conformations
depending on pH and other cellular environmental con-
ditions, thereby conferring conformational plasticity to
the oncoprotein [37,38]. The plasticity derives directly
from the capability of a a-helix to undergo b-sheet tran-
sitions, thus modifying the local structure to optimize
the interaction with other proteins. In this regard, it can
be hypothesized that, by virtue of their capacity to bind
to the E7 NH2-terminus, these scFvs can counteract the
conformational shift thereby preventing interaction with
other cellular targets.
Conclusions
T h ea n t i - p r o l i f e r a t i v ec a p a c i t yo ft h et w oa n t i - E 7s c F v s
with different epitope specificity, reported in this study,
might contribute to paving the way for the design of
therapeutic molecules against HPV-associated cancers,
an approach which should not be by any means under-
valued in the near future. Considering the epitope map-
ping results together, we can draw the conclusion that
both the scFv 43M2 and scFv 51 bind to a region map-
ping in the 16E7 NH2-terminal half but not correspond-
i n gt ot h ep R bb i n d i n gs i t e ;h o w e v e r ,o t h e rr e g i o n s
located upstream and downstream the pRb binding site,
and probably involved in determining the secondary
structure of E7, seem to contribute to this binding, and
may well interfere with the E7 binding to pRb. When
expressed intracellularly, the two scFvs may work by
inhibiting various activities of the E7 protein. It is also
possible that their contribution is different in different
kinds of tumors and experimental systems. Elucidation
of the targets involved in this inhibition and further
investigations on the mechanism of the functioning of
the scFvs are definitely required. Importantly, the possi-
bility of expressing the scFvs in different cellular com-
partments offers the chancet om o d u l a t et h e i ra c t i o n
according to the target localization. ScFvs with different
binding specificity could be employed either indepen-
dently, to discriminate the different functions of E7 thus
gaining an insight into the mechanism of E7-mediated
deregulation of cell proliferation, or in combination, to
enhance their anti-E7 activity. Finally, as stability of the
recombinant antibodies is an important issue for their
bioavailability, the possible use of scFvs-expressing con-
structs would represent an advantage in terms of deliv-
ery of therapeutic molecules in clinics.
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